140406-65-1

Basic information

• Product Name: 2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline
• Synonyms: 2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline;2-Oxiranylmethyl-1,2,3,4-tetrahydro-isoquinoline
• CAS NO: 140406-65-1
• Molecular Formula: C₁₂H₁₅NO
• Molecular Weight: 189.2536
• Mol File: 140406-65-1.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline(140406-65-1)
• EPA Substance Registry System: 2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline(140406-65-1)

Safety Data

• Hazardous Substances Data: 140406-65-1(Hazardous Substances Data)

Usage

Molecular structure

A complex structure containing a tetrahydroisoquinoline ring system.

Tetrahydroisoquinoline ring

A common motif found in many natural products and pharmaceuticals.

Oxiran-2-ylmethyl group

Indicates the presence of an epoxide functional group.

Epoxide functional group

Reactive and commonly found in various organic molecules.

Potential applications

May have uses in medicinal chemistry and drug discovery due to structural features and potential for biological activity.

Further research needed

To determine potential uses and effects.

Upstream product

• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 106-89-8 epichlorohydrin 
• 3132-64-7 1,2-Epoxy-3-bromopropane 
• 152333-94-3 glycidyl nosylate 

Downstream Products

• 1616075-00-3 3-(2-((3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)amino)-2-oxoethoxy)benzamide 
• 1616074-97-5 2-(3-acetamidophenoxy)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)acetamide 
• 1616074-91-9 N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-2-methyl-2-phenoxypropanamide 
• 1616074-90-8 2-(cyclohexyloxy)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)acetamide 
• 1616074-87-3 2-(4-acetamidophenoxy)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)acetamide 
• 1616074-86-2 N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-2-(3-methoxyphenoxy)acetamide 
• 1616074-85-1 N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-2-phenoxypropanamide 
• 1616074-81-7 N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-2-(o-tolyloxy)acetamide 
• 1616074-78-2 N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-2-(4-methoxyphenoxy)acetamide 
• 1616074-75-9 N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-2-(p-tolyloxy)acetamide 
• 1616074-74-8 2-(3-cyanophenoxy)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)acetamide 
• 1616074-73-7 N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-2-(3-fluorophenoxy)acetamide 
• 1616074-67-9 N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-2-phenoxyacetamide 
• 1616075-20-7 N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-2-(3-(1-methyl-1H-pyrazol-5-yl)phenyl)acetamide 

Relevant articles and documents

Preparation and application of sulfanilamide and benzothiazole compounds containing tetrahydroisoquinoline

The invention discloses a sulfanilamide compound, containing tetrahydroisoquinoline, shown as figure 1, and a benzothiazole compound, containing tetrahydroisoquinoline, shown as figure 2, and application of the sulfanilamide compound and the benzothiazole compound as novel protein arginine methyltransferase 5 inhibitors.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666

The recent publication of a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) provides the scientific community with in vivo-active tool compound EPZ015666 (GSK3235025) to probe the underlying pharmacology of this key enzyme. Herein, we report the design and optimization strategies employed on an initial hit compound with poor in vitro clearance to yield in vivo tool compound EPZ015666 and an additional potent in vitro tool molecule EPZ015866 (GSK3203591).